ADMA - ADMA Biologics: An Undervalued Pick For 2020
Today, we will study why ADMA Biologics (ADMA) is a promising biotech player in 2020.
Company overview
ADMA Biologics is a vertically-integrated biopharmaceutical company focused on developing and commercializing plasma-based therapeutics for the immunocompromised patient population.
The company has three commercialized products, Asceniv, Bivigam, and Nabi-Hb. In December 2019, the company was added to the Nasdaq Biotechnology Index.
What is ADMA Biologics' addressable market opportunity?
ADMA estimates the size of the U.S. IG (Immune Globulin) market was $5.9 billion in 2017. The company expects the market to grow at CAGR (compounded average